Quest PharmaTech Inc (TSXV:QPT) Stock Price, Trades & News

Quest PharmaTech Inc is developing targeted cancer therapy with its product (MAb AR9.6), under development for a novel target (truncated O-glycans on MUC16) discovered at the University of Nebraska Medical Center.

Financial Strength

Name	Current	Vs Industry
Cash-To-Debt	0.01
Equity-to-Asset	0.95
Debt-to-Equity	0.04
Debt-to-EBITDA	0.2
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
WACC vs ROIC		WACC ROIC

Growth Rank

	Name	Current	Vs Industry		Vs History
	3-Year FCF Growth Rate	30.7
	3-Year Book Growth Rate	0.9

Momentum Rank

	Name	Current	Vs Industry		Vs History
	5-Day RSI	20.27
	9-Day RSI	32.47
	14-Day RSI	37.24
	3-1 Month Momentum %	-37.5
	6-1 Month Momentum %	-28.57
	12-1 Month Momentum %	-44.44

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	0.02
	Quick Ratio	0.02
	Cash Ratio	0.01

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History
	ROE %	21.75
	ROA %	20.67
	ROIC %	-2.84
	3-Year ROIIC %	7.98
	ROCE %	21.84
	Years of Profitability over Past 10-Year	2
	Moat Score	3

GF Value Rank

	Name	Current	Vs Industry		Vs History
	PE Ratio	0.66
	PE Ratio without NRI	2
	Shiller PE Ratio	1.18
	Price-to-Owner-Earnings	0.83
	PB Ratio	0.13
	Price-to-Tangible-Book	0.13
	EV-to-EBIT	0.87
	EV-to-EBITDA	0.87
	EV-to-FCF	-27.3
	Price-to-Projected-FCF	0.2
	Price-to-Graham-Number	0.11
	Earnings Yield (Greenblatt) %	114.77
	FCF Yield %	-5.65

Financials

Annual Quarterly TTM

TSXV:QPT's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Quest PharmaTech Inc Executives

Details

GF Value™

TSXV:QPT

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with QPT. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil C$)
	EPS (TTM) (C$)	0.03
	Beta	0.0037
	3-Year Sharpe Ratio	0.03
	3-Year Sortino Ratio	0.05
	Volatility %	55.53
	14-Day RSI	37.24
	14-Day ATR (C$)	0.001501
	20-Day SMA (C$)	0.02325
	12-1 Month Momentum %	-44.44
	52-Week Range (C$)	0.02 - 0.05
	Shares Outstanding (Mil)	169.13

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	4
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Quest PharmaTech Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Quest PharmaTech Inc Stock Events

Financials Calendars

	Event	Date	Price (C$)
No Event Data

Quest PharmaTech Inc Frequently Asked Questions

What is Quest PharmaTech Inc(TSXV:QPT)'s stock price today?

The current price of TSXV:QPT is C$0.02. The 52 week high of TSXV:QPT is C$0.05 and 52 week low is C$0.02.

When is next earnings date of Quest PharmaTech Inc(TSXV:QPT)?

The next earnings date of Quest PharmaTech Inc(TSXV:QPT) is .

Does Quest PharmaTech Inc(TSXV:QPT) pay dividends? If so, how much?

Quest PharmaTech Inc(TSXV:QPT) does not pay dividend.

Press Release

	Subject	Date
	OncoQuest Pharmaceuticals Inc. Announces First Patient Enrolled in Each of Two Investigator Initiated Clinical Trials of Oregovomab in Combination Therapy for the Treatment of Recurrent Ovarian Cancer	2021-09-01
	Quest PharmaTech announces two presentations by OncoQuest Pharmaceuticals, Inc. at the 2021 Annual Meeting of the American Association of Clinical Oncologists	2021-06-01
	Quest Announces that OncoQuest Pharmaceuticals Inc. Doses First Patient in Phase 3 Clinical Trial, FLORA-5, of Company's Lead Investigational Drug, Oregovomab, in Frontline Ovarian Cancer and appoints Dr. Sunil Gupta as Chief Medical Officer	2020-11-09
	OncoQuest Announces Publication of Two Reports Related to Oregovomab Phase 2 Clinical Trial, the Company's Lead Investigational Drug in Frontline Ovarian Cancer	2020-03-24
	OncoQuest Announces a U.S.$50 Million Investment by KOSDAQ listed Dual Industrial Co. Ltd.	2020-03-13
	OncoQuest Receives "Notice of Allowance" for Patent Protection of the Administration Schedule of Oregovomab and Chemotherapy for Stage III-IV Ovarian Cancer Patients	2019-09-25
	OncoQuest Lays the Groundwork for Commencement of Phase 3 Study in Frontline Ovarian Cancer	2019-01-25
	Quest PharmaTech Signs License Agreement with OncoCare Therapeutics to Develop and Commercialize Targeted Cancer Therapy Technology in the U.S.	2018-11-28
	Abstract Describing Use of Oregovomab in Pancreatic Cancer to be Published in JCO as Part of ASCO 2018 Meeting	2018-06-01
	Dr. Eliel Bayever Joins OncoQuest as Chief Medical Officer	2018-05-14

10/Page

Articles on Quest PharmaTech Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.